SAN DIEGO, Aug. 3 /PRNewswire-FirstCall/ —
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) announced the online publication of results
from its COR-BMOD trial of Contrave® (naltrexone SR/bupropion
SR) in the journal Obesity. The COR-BMOD trial evaluated
intensive behavior modification (BMOD) plus Contrave32 (32mg
naltrexone sustained release (SR)/360mg bupropion SR) compared to
BMOD plus placebo, in 793 overweight or obese patients. The
addition of Contrave to BMOD delivered significant incremental
weight loss and improvements in measures of cardiometabolic risk.
Results showed that patients taking Contrave lost 9.3% of
their body weight compared to 5.1% for patients on placebo (p<
0.001), on an intent-to-treat basis. For those who completed
56 weeks of treatment, patients taking Contrave plus BMOD lost
11.5% of their body weight compared to 7.3% for those taking
placebo (p<0.001).
Behavior modification, including diet and exercise, has long
been considered the standard of care in managing obesity. The
benefit of adding specific pharmacotherapies to a rigorous BMOD
program has not been extensively evaluated. COR-BMOD was
designed to test this hypothesis by evaluating Contrave in a
setting conducive to maximum weight loss in which patients used the
medication as part of a broader weight-loss effort.
Participants in both groups received diet and exercise
counseling during 28 small group sessions with one or two
professionals, each lasting 90 minutes, over the course of the
year-long trial.
“There is no magic bullet for the treatment of obesity.
For some patients, effective and sustainable treatment is
going to require a multi-modal approa
‘/>”/>
SOURCE